Background
==========

It has been hypothesized \[[@B1]-[@B3]\] that cancer cells become invasive and migratory by undergoing some type of epithelial-mesenchymal transition (EMT) reactivating early embryogenesis programs. Each type of EMT is assumed to be orchestrated by different unknown combinations of multiple interacting transcription factors and signaling pathways. A set of genes comprising an \"EMT core signature\" was recently derived \[[@B4]\] after triggering EMTs in different ways and observing the resulting shared changes in gene expression. However, the details of the specific types of EMT associated with cancer invasion remain elusive and complicated by the difficulty of detecting signs of EMT in human cancer cells, and the topic remains controversial.

A multi-cancer gene expression signature involving a large set of genes, several among them being EMT markers coordinately overexpressed only in a subset of malignant samples that have exceeded a particular staging threshold specific to each cancer type was recently identified \[[@B5]\]. The signature is present in numerous publicly available datasets from multiple cancer types from all solid tumor types that we tried, including nonepithelial cancers such as neuroblastoma and Ewing\'s sarcoma but not in leukemia. Examples of heat maps are shown for breast \[see Additional file [1](#S1){ref-type="supplementary-material"}\], colon \[see Additional file [2](#S2){ref-type="supplementary-material"}\], Ewing\'s sarcoma \[see Additional file [3](#S3){ref-type="supplementary-material"}\], lung \[see Additional file [4](#S4){ref-type="supplementary-material"}\], ovarian \[see Additional file [5](#S5){ref-type="supplementary-material"}\], neuroblastoma \[see Additional file [6](#S6){ref-type="supplementary-material"}\] and leukemia \[see Additional file [7](#S7){ref-type="supplementary-material"}\], demonstrating the remarkable co-expression of the genes in solid tumors. Among the overexpressed genes are the EMT inducing transcription factor Slug (SNAI2), various collagens and proteinases, α-SMA, fibronectin, fibroblast activation protein, and many extracellular matrix glycoproteins, suggesting a fibroblastic nature after passing through a Slug-based EMT.

The signature, however, has its own special characteristics, one of which is that the strongly co-expressed genes *COL11A1*, *THBS2*and *INHBA*have a prominent presence. Collagen *COL11A1*was found to be a reliable proxy for the signature: in each solid tumor dataset that we tried, the list of genes whose expression is most highly correlated (using measures such as mutual information \[[@B6]\] or Pearson correlation) with that of *COL11A1*consistently includes the other genes of the signature at the top, with the only exception of glioblastoma in which *COL11A1*is not as prominently co-expressed with the other genes, though the signature is still present otherwise. Notably, E cadherin (*CDH1*) is not downregulated at least at the mRNA level. Furthermore, the signature contains numerous other EMT associated genes. Table [1](#T1){ref-type="table"} identifies the known EMT markers among the list of the 64 genes corresponding to the 100 most overexpressed probe sets previously reported \[[@B5]\], of the signature. Highlighted by bold typeface among these 64 are 20 known EMT-associated genes, 17 coming from the list of 91 upregulated \"EMT core signature\" \[[@B4]\] genes (*COL5A2*, *FAP*, *POSTN*, *COL1A2*, *COL3A1*, *FBN1*, *TNFAIP6*, *MMP2*, *GREM1*, *BGN*, *CDH11*, *SPOCK1*, *DCN*, *COPZ2*, *THY1*, *PCOLCE*, *PRRX1*) plus the obvious EMT markers *SNAI2*, *FN1*, *ACTA2*. Four additional genes (underlined but not bold in Table [1](#T1){ref-type="table"}), *PDGFRB*, *SPARC*, *INHBA*, *COL6A2*, have also been reported as EMT-related \[[@B7]\], for a total of 24 EMT factors. Even without including these additional seven genes, the *P*value of encountering 17 out of 64 genes taken from the list of the 91 EMT core signature genes is 2 × 10^-22^. Therefore, this fibroblastic signature is the result, at least in part, of an EMT.

###### 

Top genes overexpressed in the fibroblastic signature (see text for designation with boldface and underline)

  Rank   Probe set      Gene           Rank   Probe set      Gene
  ------ -------------- -------------- ------ -------------- ---------------
  1      37892_at       COL11A1        33     202998_s\_at   LOXL2
                                                             
  2      203083_at      THBS2          34     201438_at      COL6A3
                                                             
  3      217428_s\_at   COL10A1        35     209596_at      MXRA5
                                                             
  4      221729_at      **COL5A2**     36     213764_s\_at   MFAP5
                                                             
  5      210511_s\_at   [INHBA]{.ul}   37     204589_at      NUAK1
                                                             
  6      213909_at      LRRC15         38     217762_s\_at   RAB31
                                                             
  7      212488_at      COL5A1         39     201150_s\_at   TIMP3
                                                             
  8      204619_s\_at   VCAN           40     221541_at      CRISPLD2
                                                             
  9      209955_s\_at   **FAP**        41     205422_s\_at   ITGBL1
                                                             
  10     202311_s\_at   COL1A1         42     207173_x\_at   **CDH11**
                                                             
  11     203878_s\_at   MMP11          43     213338_at      TMEM158
                                                             
  12     210809_s\_at   **POSTN**      44     202363_at      **SPOCK1**
                                                             
  13     202404_s\_at   **COL1A2**     45     204051_s\_at   SFRP4
                                                             
  14     202952_s\_at   ADAM12         46     202283_at      SERPINF1
                                                             
  15     215076_s\_at   **COL3A1**     47     209335_at      **DCN**
                                                             
  16     215446_s\_at   LOX            48     219655_at      C7orf10
                                                             
  17     210495_x\_at   **FN1**        49     219561_at      **COPZ2**
                                                             
  18     201792_at      AEBP1          50     219773_at      NOX4
                                                             
  19     212353_at      SULF1          51     204464_s\_at   EDNRA
                                                             
  20     202766_s\_at   **FBN1**       52     200974_at      **ACTA2**
                                                             
  21     219087_at      ASPN           53     202273_at      [PDGFRB]{.ul}
                                                             
  22     200665_s\_at   [SPARC]{.ul}   54     61734_at       RCN3
                                                             
  23     202450_s\_at   CTSK           55     213139_at      **SNAI2**
                                                             
  24     206026_s\_at   **TNFAIP6**    56     220988_s\_at   C1QTNF3
                                                             
  25     222020_s\_at   HNT            57     205713_s\_at   COMP
                                                             
  26     206439_at      EPYC           58     201105_at      LGALS1
                                                             
  27     201069_at      **MMP2**       59     213869_x\_at   **THY1**
                                                             
  28     205479_s\_at   PLAU           60     202465_at      **PCOLCE**
                                                             
  29     218469_at      **GREM1**      61     209156_s\_at   [COL6A2]{.ul}
                                                             
  30     201261_x\_at   **BGN**        62     221447_s\_at   GLT8D2
                                                             
  31     213125_at      OLFML2B        63     204114_at      NID2
                                                             
  32     201744_s\_at   LUM            64     205991_s\_at   **PRRX1**

The initiation of significant signature overexpression after reaching a particular cancer-type-specific stage suggests an underlying biological mechanism associated with cancer invasion. Given the heterogeneity of cells in tumors, it could also reflect the superposition of several mechanisms. Among other possibilities, the fibroblast-like cells producing the signature could be derived from multiple sources, such as the bone marrow, the local stroma, or the cancer cells after undergoing a mesenchymal transition. A fundamental question, therefore, is which among the genes of the signature are expressed by the cancer cells and which are expressed by the adjacent microenvironment.

We also observed that there is a striking similarity \[[@B8]\] between the set of genes in the signature and a subset of the genes that are known to be lower expressed when mouse embryonic fibroblasts are reprogrammed into induced pluripotent stem cells \[[@B9]\]. Because it is known \[[@B10]\] that a mesenchymal-epithelial transition (MET) is part of the reprogramming of mouse fibroblasts into stem cells, we reasoned that, conversely, the signature may correspond to some kind of EMT-related transition from a stem-like state to a fibroblast-like state used in early embryogenesis. Therefore, we hypothesized that many among the genes in the signature may be expressed by cancer stem cells (CSCs) passing through some type of EMT. Furthermore, because of the prominent presence of inhibin-A (*INHBA*) in the signature, we hypothesized that activin A (INHBA dimer) signaling may be responsible for the signature.

To test these two hypotheses and to identify which among the genes of the signature, if any, are expressed by the cancer cells, we used xenograft models implanting human cancer cell lines into NCR nude mice. Since the signature was clearly found in neuroblastoma \[see Additional file [6](#S6){ref-type="supplementary-material"}\], in which we already had successful experience of xenograft experimentation, we used a neuroblastoma cell line even though it is not strictly an epithelial tumor, as this could shed further light on the complex biological underlying mechanisms. Some of the implanted cancer cell lines were in their original form, some were engineered to express INHBA, and some were engineered to express the activin antagonist follistatin (FST). Each of the resulting growing tumors was harvested and profiled for gene expression twice using human and mouse microarrays separately. Our results validated the first hypothesis, but not the second: Most of the genes of the signature were found in human, but not mouse, cells, and their presence was independent of any transfections, indicating that activin signaling does not play a causal role.

Specifically, our experiments confirmed that the genes of the signature, Slug being prominent among them, are co-expressed across samples to various degrees covering a continuous range of values including some samples with large expression of these genes. This result is consistent with the publicly available cancer gene expression datasets. Figure [1](#F1){ref-type="fig"} shows that Slug is indeed co-expressed with the key genes *COL11A1*and *THBS2*in various cancer types, but not leukemia. The remarkable continuity of the dots shown in the scatter plots of Figure [1A-C](#F1){ref-type="fig"} suggests a dynamic and potentially reversible process as the human cancer cells pass through a mesenchymal transition process.

![**Color-coded scatter plots for the coexpression of the EMT inducing transcription factor Slug (SNAI2) The scatter plots indicate the strong co-expression with the main signature genes COL11A1 and THBS2, as well as the continuity of the passing of cancer cells through a Slug-based EMT in solid tumors, and the total absence of the co-expression of these genes otherwise**. **A**, **B**and **C**, plots from three solid tumor datasets. **D**, plot from a leukemia dataset.](1471-2407-11-529-1){#F1}

Methods
=======

Tumor implantation
------------------

An inoculum of 106 NGP neuroblastoma cells containing FUW-Luciferase plasmid (kindly donated by Dr. Adolfo Ferrando) suspended in 0.1 mL of phosphate-buffered saline (PBS) was injected into the left kidney of 18 mice. The NGP cell line was originally obtained from Garrett Brodeur, Children\'s Hospital of Philadelphia. All cells were authenticated by short tandem repeat profiling analysis. Some of the implanted cells had previously been stably co-transfected with either FST-pReceiver-Lv105 or INHBA pReceiver-Lv105 (GeneCopoeia; Rockville, MD). Seven mice were implanted with INHBA-transfected NGP cells, six with FST and five with control NGP cells. All mice experiments and breeding were conducted according to protocols approved by the Columbia University IACUC.

Harvesting of specimens
-----------------------

Mice were sacrificed when estimated tumor weight reached 1.5 g followed by collection of contralateral kidney and tumor. Tumor tissue was snap frozen for RNA isolation.

Microarrays and probes preparation
----------------------------------

HG-U133A 2.0 (human genome) and 430 A2.0 (mouse genome) Gene Chips (Affymetrix, Santa Clara, CA) were used to investigate gene expression in xenograft tumors. The cRNA probes were synthesized as recommended by Affymetrix, purified using RNeasy and fragmented according to the Affymetrix protocol, and 15 μg of biotinylated cRNA were hybridized to the microarrays. The samples were scanned with Affymetrix Gene Chip Scanner 3000.

RNA isolation and semiquantitative reverse transcription-PCR
------------------------------------------------------------

Total RNA was isolated from tumors using Qiagen miRNeasy mini kit (Qiagen, Germantown, MD) followed by reverse transcription using SuperScript First-Strand synthesis System for RT-PCR from Invitrogen according to manufacture recommendations (Carlsbad, CA, USA). Relative expression of human versus mouse COL11A1 (Hs00266273_m1, Ms00483387_m1) genes in tumor xenografts were examined by RT-PCR. Products were detected by Hot Start-IT Probe qPCR Master Mix from USB Affymetrix (Santa Clara, CA) according to manufacture instructions and analyzed by Stratagene Mx3005p real time PCR machine. After scanning, expression values for genes were determined using MxPro 410 (Agilent Technologies, Inc., Santa Clara, CA). Human HPRT, CYC, GAPD and mouse GAPD, ACTB, GUSB expression values were used to correct for sample variations in RT-PCR efficiency and errors in quantitation.

Microarray dataset
------------------

The data set, corresponding to 18 tumors profiled separately with human and mouse microarrays, has been deposited in NCBI\'s Gene Expression Omnibus (GEO) and is available through accession number GSE34481. Data were RMA normalized using the Bioconductor open source software.

Differential expression analysis
--------------------------------

We regrouped the 18 samples, according to the expression level of human COL11A1, into seven samples with high or intermediate COL11A1 expression values, and eleven with low COL11A1 expression values. Based on this partition, we performed differential expression analysis using significance analysis of microarrays (SAM) \[[@B11]\], implemented in the Bioconductor package samr. We define the significantly differentially expressed gene as those having both a *Q*value less than 0.05 and a fold-change greater than 2.

Results
=======

We found very different expression levels (Figure [2](#F2){ref-type="fig"}) for most genes in human and mouse, suggesting that interspecies hybridization is minimal, as previously reported \[[@B12]\], which was confirmed with real-time PCR (see Materials and Methods and Figure [3](#F3){ref-type="fig"}). Using COL11A1 as a proxy, we ranked the 18 samples accordingly and investigated if most of the genes in Table [1](#T1){ref-type="table"} were co-expressed with *COL11A1*. We found that this was indeed the case in human cells only. For example, Figures [2A-B](#F2){ref-type="fig"} show color-coded scatter plots in human and mouse of the 18 samples for the expression of Slug (*SNAI2*) in terms of the expression of the main genes of the signature, *COL11A1*and *THBS2*(same as in the scatter plots of Figure [1](#F1){ref-type="fig"} suggesting an identical biological process) demonstrating that this co-expression is clearly present in the human cells, but absent in the mouse cells. Specifically, seven samples had high or intermediate levels of co-expressed genes in the human cells, while the remaining 11 have relatively lower levels.

![**Color-coded scatter plots in human and mouse of the 18 samples for Slug expression The expression of the EMT inducing transcription factor Slug (SNAI2) is shown in terms of the expression of the main signature genes COL11A1 and THBS2**. **A**, demonstration that this co-expression is present in the xenografted human cells. **B**, demonstration that this co-expression is absent in the peritumoral mouse cells. **C**, Bar diagram indicating that other EMT inducing transcription factors are not co-expressed.](1471-2407-11-529-2){#F2}

![**Quantitative PCR Shown is the expression of human COL11A1 (**A**) or mouse COL11A1 (**B**) in RNA samples isolated from tumor NGP xenografts (number indicated)**. Expression of human COL11A1 increased in samples from left to right consistent with microarray results. Data were normalized to the expression of human HPRT. Mouse COL11A1 was not expressed in samples. Data was normalized to the expression of mouse Actb. Graphs depicted as relative levels of human (**A**) or mouse (**B**) control reference RNA.](1471-2407-11-529-3){#F3}

Based on this partition, we identified 398 significantly (both Q \< 0.05 and FC \> 2) up-regulated genes, 29 among which (*COL11A1*, *THBS2*, *COL5A2*, *COL5A1*, *VCAN*, *COL1A1*, *COL3A1*, *FN1*,*SULF1*, *FBN1*, *ASPN*, *SPARC*, *CTSK*, *MMP2*, *BGN*, *LUM*, *LOXL2*, *COL6A3*, *TIMP3*, *CDH11*, *SERPINF1*, *EDNRA*, *ACTA2*, *PDGFRB*, SNAI2, *LGALS1*, *GLT8D2*, *NID2*, *PRRX1*) belong to the set of 64 genes in Table [1](#T1){ref-type="table"} (*P*= 10^-27^), as well as *VIM*(vimentin). The presence in this list of *SNAI2*(Slug), *ACTA2*(α-SMA), *FN1*(fibronectin), *VIM*(vimentin), together with many of the other EMT markers mentioned above, indicates that some human cancer cells underwent EMT. Other EMT-inducing transcription factors (Snail, Twist, ZEB1, ZEB2, SIP1, FOXC2) were not upregulated (Figure [2C](#F2){ref-type="fig"}C), while the upregulation of SNAI2 (Figure [2A](#F2){ref-type="fig"}) was very significant (*Q*\< 3 × 10^-4^and FC = 5.22).

The heat map in Figure [4](#F4){ref-type="fig"} shows the co-expression of the above 29 significantly upregulated genes. *INHBA*, the third prominent gene of the signature in addition to *COL11A1*and *THBS2*, is not included in the list, because its expression was manipulated by the transfections with consistent results. Furthermore, the transfections of cancer cells with either INHBA (labeled I) or FST (labeled F) did not have any effect on the presence of the signature (the corresponding expression levels were consistent with the transfections and did not affect the expression of the other genes in the signature).

![**Heat map combining human and mouse genes**. The 29 human genes include many EMT factors and were found to be significantly co-expressed in the cancer cells.](1471-2407-11-529-4){#F4}

These same 29 genes are used in the heat maps shown in the Additional files, suggesting that the same signature may be expressed in all solid tumors, even in nonepithelial tumors, such as neuroblastoma and Ewing\'s sarcoma. Therefore, our results imply that the underlying mesenchymal transition process is more general than what EMT is presumed to be.

We next analyzed the mouse microarray data to identify genes correlated with the presence of the cancer EMT signature in the human cells. We found 32 significantly (both *Q*\< 0.05 and FC \> 2) downregulated mouse genes in the presence of the human cancer EMT signature. Among them, the top two genes with the highest fold change (12.3 and 11.8 respectively) were the adipocyte markers adiponectin (*ADIPOQ*) and adipsin (*CFD*). We observed that these genes were strongly co-regulated with many other adipocyte markers, including fatty acid binding protein 4 (*FABP4*) aka *aP2*. This cluster of adipocyte markers whose downregulation in the mouse cells is strongly associated with the upregulation of the EMT signature genes in human cells is also shown in the heat map of Figure [4](#F4){ref-type="fig"}. Many among these genes are known as adipocyte differentiation markers, and their downregulation is consistent with the finding that adipocytes are dedifferentiated as they encounter adjacent invading cancer cells in a \"vicious cycle\" \[[@B13]\] of a complex interaction facilitating cancer cell invasiveness. The observed downregulation of adipocyte markers in the adjacent mouse tissue, associated with the EMT-specific gene expression of the human cells provides a potential molecular control mechanism of microenvironmental contextual interactions in accordance with previously published results.

In summary, we have shown that a precise multi-cancer EMT signature present in numerous publicly available datasets was found in our xenograft experiments not to be expressed by the stromal cells, but instead by the human cancer cells themselves in vivo. Prior to our experiments, this was an open question. Indeed, similar signatures were usually referred to as \"stromal,\" because they contain genes, such as a-SMA, that are typically found in stromal cells such as fibroblasts. Therefore, our results are consistent with the hypothesis that an EMT can convert cancer cells into mesenchymal, fibroblast-like cells that may well assume the duties of cancer-associated fibroblasts in some tumors \[[@B14]\]. Of additional significance is the knowledge of the precise composition of this particular Slug-based signature (as found both in our xenograft experiments as well as numerous cancer datasets) as it provides opportunities for identifying potential targets for inhibiting the underlying biological mechanism of mesenchymal transition of cancer cells.

Discussion
==========

The quality of \"stemness\" in cells appears to be closely interconnected with the ability to pass through transitions to and from mesenchymal characteristics. Indeed, EMT generates cells with properties of stem cells \[[@B15]\] and, conversely, MET is involved in the reprogramming of fibroblasts into stem cells \[[@B10]\]. Therefore, we speculate \[[@B8]\] that the cancer mesenchymal transition signature identified in this work may initiate from CSCs, which may even appear spontaneously \[[@B16]\]. It is also possible that the adipocytes of the stroma adjacent to the tumor are dedifferentiated into a mesenchymal stem cell-like state and, together with other mesenchymal stem cells derived from the bone marrow \[[@B17]\] interact with the invading fibroblastic cancer cells in a manner that reactivates a particular early embryonic developmental program.

Not all genes in Table [1](#T1){ref-type="table"} are upregulated in the human cells. For example, *PLAU*(urokinase plasminogen activator) is slightly upregulated only in mouse cells consistently with its assumed role of being secreted by reactive stromal cells as a pro-enzyme that activates itself and other proteases in the presence of cancer cells.

Another prominent gene of the signature observed in public databases that was not upregulated in the human xenografted cells is *MMP11*(matrix metallopeptidase 11, aka stromelysin 3), in agreement with the hypothesis \[[@B13],[@B18],[@B19]\] that MMP11 is expressed in the adipocytes of the adjacent reactive stroma, indicating that the full version of the cancer mesenchymal transition signature may be stabilized by contextual microenvironmental signals when cancer cells encounter adipocytes triggering their dedifferentiation, apoptosis, or metabolism \[[@B13]\]. The expression in cancer cells of the adipocyte enhancer binding protein 1 (AEBP1), a prominent gene of the signature known to bind in the promoter region of the adipocyte fatty-acid protein FABP4 may play an important role in that respect, as may also the presence of oxidative stress and TNF signaling suggested by the presence of TNFAIP6 and C1QTNF3 in the signature.

The hypothesis that the mesenchymal transition signature is triggered by adipocytes is consistent with the facts \[[@B5]\] that in breast cancer the signature overexpression appears immediately upon reaching invasive stage I, while in ovarian cancer overexpression appears only when the tumor is already well into stage III as in omental metastasis, because ovarian cancer initially progresses by disseminating locally across mesothelial surfaces and probably carried by the physiological movement of peritoneal fluid to the peritoneum and omentum, a fatty structure \[[@B20]\].

The remarkable continuity of the signature (Figures [1](#F1){ref-type="fig"} and [2](#F2){ref-type="fig"}) suggests that it may reflect a reversible process in which the mesenchymal markers in the cancer cells may appear and disappear depending on microenvironmental contextual signals. Its potential reversal is consistent with the possibility that passing through this mesenchymal transition at some point is a requirement for the initial stage of all metastases, even though the signature is significantly observed only in a subset of high-stage extracted samples at any given time. In other words, the lack of the signature in a particular extracted sample does not imply that cancer is not invasive, because the signature may have appeared earlier. However, the presence of the signature implies that the cancer is invasive; therefore a potential related biomarker product would have high selectivity, but not sensitivity.

Conclusions
===========

Many among the genes of the signature expressed by the human xenografted cells have previously been individually identified as associated with metastatic potential in cancer. Such associations can now largely be explained by the fact that these genes are expressed by the cancer cells themselves undergoing a mesenchymal transition. The known precise composition of the signature, particularly when combined with its separation in a species-specific manner in xenograft models, provides multiple and unique opportunities for understanding the underlying biological mechanisms and identifying diagnostic and prognostic markers as well as potential targets for metastasis-inhibiting therapeutics.
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###### Additional file 1

**Heat map of breast cancer data set This file contains the heat map of the TCGA breast cancer data set for the genes of the mesenchymal transition signature**.
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###### Additional file 2

**Heat map of colon cancer data set This file contains the heat map of the TCGA colon cancer data set for the genes of the mesenchymal transition signature**.
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###### Additional file 3

**Heat map of Ewing\'s sarcoma data set This file contains the heat map of a Ewing\'s sarcoma data set (GEO accession number GSE12102) for the genes of the mesenchymal transition signature**.
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###### Additional file 4

**Heat map of lung cancer data set This file contains the heat map of the TCGA lung cancer data set for the genes of the mesenchymal transition signature**.
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###### Additional file 5

**Heat map of ovarian cancer data set This file contains the heat map of the TCGA ovarian cancer data set for the genes of the mesenchymal transition signature**.
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###### Additional file 6

**Heat map of neuroblastoma data set This file contains the heat map of a neuroblastoma data set (GEO accession number GSE3960) for the genes of the mesenchymal transition signature**.
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###### Additional file 7

**Heat map of leukemia data set This file contains the heat map of the TCGA leukemia data set for the genes of the mesenchymal transition signature**.
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